Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic HBV Infection
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is an open label, randomized, parallel-group study to evaluate the safety and efficacy
of combination treatment BRII-835 (VIR-2218) and BRII-179 (VBI-2601) in adult participants
with chronic HBV infection